LLY vs BMY
By Alex · Tickerpine
Eli Lilly and Company vs Bristol-Myers Squibb Company, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | BMY |
|---|---|---|
| Price | $1,443.50 | $63.43 |
| Market cap | $1.29T | $129.66B |
| P/E ratio | 46.9 | 14.1 |
| ROE | 86.02% | 44.01% |
| Profit margin | 31.90% | 18.47% |
| Revenue growth | 38.60% | 6.90% |
| Dividend yield | 0.48% | 3.97% |
| Beta | 0.39 | 0.19 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs BMY in plain English
- LLY is the bigger company — about 9.9× the market cap of BMY.
- BMY is cheaper on earnings (P/E 14.1 vs 46.9).
- LLY earns a higher return on equity (86% vs 44%).
- LLY is growing revenue faster (39% vs 7%).
- BMY has the higher dividend yield (3.97% vs 0.48%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
BMY return calculator
See what $1,000 in Bristol-Myers Squibb Company would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.